IPO - Profile


We are a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Far too many individuals – patients and caregivers – suffer from the burden created by these devastating, and often fatal, diseases. Our primary target, Alzheimer’s disease, was among the most-feared diseases (second only to cancer) among Americans, according to a 2011 survey by the More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$5.00 2,500,000 Positive High 20.44%

Offering Team

  • Legal counsel
  • Olshan Frome Wolosky LLP
  • Auditors
  • Squar Milner LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 14 Jun, 2021

Offer 15 Jun, 2021

Look Ahead

Lock Up Expiry Dec 15, 2021

IPO Terms

Offer Price $5.00
Offer Size 2M

Market Sentiments

Stock Price